Brokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) PT at $56.36

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the fifteen ratings firms that are presently covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $56.36.

Several analysts have weighed in on the stock. HC Wainwright upped their price objective on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Citigroup started coverage on shares of Kymera Therapeutics in a report on Thursday, March 13th. They set a "buy" rating and a $52.00 price objective on the stock. Finally, Stephens reiterated an "overweight" rating and set a $60.00 target price on shares of Kymera Therapeutics in a research report on Tuesday, January 21st.

Insider Buying and Selling

In other news, COO Jeremy G. Chadwick sold 1,383 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $42,112.35. Following the sale, the chief operating officer now owns 67,800 shares of the company's stock, valued at $2,064,510. The trade was a 2.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Ellen Chiniara sold 2,241 shares of the firm's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $68,238.45. Following the completion of the transaction, the insider now directly owns 80,085 shares of the company's stock, valued at approximately $2,438,588.25. This trade represents a 2.72 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,659 shares of company stock valued at $324,567. Company insiders own 15.82% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP raised its position in Kymera Therapeutics by 14.9% during the fourth quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company's stock worth $213,514,000 after acquiring an additional 688,967 shares in the last quarter. Avoro Capital Advisors LLC increased its stake in shares of Kymera Therapeutics by 14.4% during the 4th quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company's stock worth $207,184,000 after purchasing an additional 650,000 shares during the last quarter. Deerfield Management Company L.P. Series C acquired a new position in shares of Kymera Therapeutics during the 4th quarter worth about $23,856,000. Boxer Capital Management LLC bought a new stake in shares of Kymera Therapeutics in the 4th quarter valued at about $17,098,000. Finally, Janus Henderson Group PLC lifted its stake in Kymera Therapeutics by 2,397.9% in the 4th quarter. Janus Henderson Group PLC now owns 377,384 shares of the company's stock valued at $15,197,000 after purchasing an additional 362,276 shares during the last quarter.

Kymera Therapeutics Price Performance

Shares of KYMR traded down $5.01 during mid-day trading on Friday, reaching $28.57. The company had a trading volume of 1,352,064 shares, compared to its average volume of 560,653. The company has a market capitalization of $1.86 billion, a P/E ratio of -12.21 and a beta of 2.18. Kymera Therapeutics has a twelve month low of $19.45 and a twelve month high of $53.27. The company's 50-day moving average is $29.64 and its 200-day moving average is $38.03.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The company had revenue of $7.39 million for the quarter, compared to analyst estimates of $14.81 million. As a group, equities analysts expect that Kymera Therapeutics will post -2.79 EPS for the current fiscal year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.